QT Interval Prolongation Risk with Citalopram and Sotalol Combination

Mechanism and Clinical Significance

• The combination of citalopram and sotalol has an additive QT-prolonging effect, significantly increasing the risk of life-threatening arrhythmias, according to the European Heart Journal 1, 2
• Both citalopram and sotalol are considered Class B* drugs (with pronounced QT prolongation, documented cases of Torsade de Pointes, or other serious arrhythmias) by the European Heart Journal guidelines 1, 3

Risk Factors and Management

• Renal insufficiency is a risk factor for adverse outcomes in patients taking the combination of citalopram and sotalol, as reported in Circulation 4
• The American Heart Association, as reported in Circulation, suggests considering alternative antiarrhythmic agents with less QT prolongation potential when treating patients with arrhythmias 6, 4
• The American Academy of Child and Adolescent Psychiatry recommends considering alternative SSRIs with lower QT prolongation risk, such as sertraline, instead of citalopram 5